Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
Kezar Life Sciences Net Income (Quarterly) : -5.756M for March 31, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -5.756M |
| December 31, 2025 | -14.55M |
| September 30, 2025 | -11.23M |
| June 30, 2025 | -13.70M |
| March 31, 2025 | -16.56M |
| December 31, 2024 | -20.22M |
| September 30, 2024 | -20.31M |
| June 30, 2024 | -21.55M |
| March 31, 2024 | -21.66M |
| December 31, 2023 | -32.26M |
| September 30, 2023 | -23.10M |
| June 30, 2023 | -24.31M |
| March 31, 2023 | -22.20M |
| December 31, 2022 | -18.18M |
| September 30, 2022 | -17.85M |
| June 30, 2022 | -16.19M |
| March 31, 2022 | -16.02M |
| December 31, 2021 | -14.21M |
| September 30, 2021 | -14.46M |
| Date | Value |
|---|---|
| June 30, 2021 | -12.96M |
| March 31, 2021 | -12.99M |
| December 31, 2020 | -10.94M |
| September 30, 2020 | -11.29M |
| June 30, 2020 | -9.50M |
| March 31, 2020 | -10.01M |
| December 31, 2019 | -9.579M |
| September 30, 2019 | -9.148M |
| June 30, 2019 | -8.718M |
| March 31, 2019 | -7.642M |
| December 31, 2018 | -5.782M |
| September 30, 2018 | -5.663M |
| June 30, 2018 | -6.775M |
| March 31, 2018 | -4.947M |
| December 31, 2017 | -2.30M |
| September 30, 2017 | -2.08M |
| June 30, 2017 | -1.88M |
| March 31, 2017 | -2.257M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0858M |
| Brainstorm Cell Therapeutics, Inc. | -3.855M |
| Summit Therapeutics, Inc. | -215.70M |
| Protara Therapeutics, Inc. | -21.67M |
| Clene, Inc. | -13.42M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.756M |
| EPS Diluted (Quarterly) | -0.7838 |
| Enterprise Value | -11.12M |
| Earnings Yield | -84.73% |
| Normalized Earnings Yield | -74.78 |